Koehn Brent H, Apostolova Petya, Haverkamp Jessica M, Miller Jeffrey S, McCullar Valarie, Tolar Jakub, Munn David H, Murphy William J, Brickey Willie June, Serody Jonathan S, Gabrilovich Dmitry I, Bronte Vincenzo, Murray Peter J, Ting Jenny P-Y, Zeiser Robert, Blazar Bruce R
Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN;
Department of Hematology and Oncology, Freiburg University Medical Center, Albert-Ludwigs-University, Freiburg, Germany;
Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.
Myeloid-derived suppressor cells (MDSCs) are a naturally occurring immune regulatory population associated with inhibition of ongoing inflammatory responses. In vitro generation of MDSCs from bone marrow has been shown to enhance survival in an acute model of lethal graft-versus-host disease (GVHD). However, donor MDSC infusion only partially ameliorates GVHD lethality. In order to improve the potential therapeutic benefit and ultimately survival outcomes, we set out to investigate the fate of MDSCs after transfer in the setting of acute GVHD (aGVHD). MDSCs transferred to lethally irradiated recipients of allogeneic donor hematopoietic grafts are exposed to an intense inflammatory environment associated with aGVHD, which we now show directly undermines their suppressive capacity. Under a conditioning regimen and GVHD inflammatory settings, MDSCs rapidly lose suppressor function and their potential to inhibit GVHD lethality, which is associated with their induced conversion toward a mature inflammasome-activated state. We find even brief in vitro exposure to inflammasome-activating mediators negates the suppressive potential of cultured murine and human-derived MDSCs. Consistent with a role for the inflammasome, donor MDSCs deficient in the adaptor ASC (apoptosis-associated speck-like protein containing a CARD), which assembles inflammasome complexes, conferred improved survival of mice developing GVHD compared with wild-type donor MDSCs. These data suggest the use of MDSCs as a therapeutic approach for preventing GVHD and other systemic inflammatory conditions will be more effective when combined with approaches limiting in vivo MDSC inflammasome activation, empowering MDSCs to maintain their suppressive potential.
髓系来源的抑制细胞(MDSCs)是一种天然存在的免疫调节细胞群,与抑制正在进行的炎症反应相关。已证明从骨髓中体外生成MDSCs可提高致死性移植物抗宿主病(GVHD)急性模型中的存活率。然而,供体MDSC输注只能部分改善GVHD的致死率。为了提高潜在的治疗益处并最终改善生存结果,我们着手研究在急性GVHD(aGVHD)情况下转移后MDSCs的命运。转移到接受致死性照射的异基因供体造血移植物受体的MDSCs暴露于与aGVHD相关的强烈炎症环境中,我们现在直接表明这种环境会破坏它们的抑制能力。在预处理方案和GVHD炎症环境下,MDSCs迅速丧失抑制功能及其抑制GVHD致死率的潜力,这与它们诱导转化为成熟的炎性小体激活状态有关。我们发现,即使在体外短暂暴露于炎性小体激活介质也会消除培养的小鼠和人源MDSCs的抑制潜力。与炎性小体的作用一致,缺乏组装炎性小体复合物的接头蛋白ASC(含CARD的凋亡相关斑点样蛋白)的供体MDSCs与野生型供体MDSCs相比,可提高发生GVHD小鼠的存活率。这些数据表明,当与限制体内MDSC炎性小体激活的方法相结合,使MDSCs能够维持其抑制潜力时,使用MDSCs作为预防GVHD和其他全身性炎症疾病的治疗方法将更有效。